The innovative therapy is based on the research of Prof. Dror Mevorach
Macrophage reprogramming, unmet medical need indications
Off-the-shelf, universal cell therapy for resetting macrophages back to their ”manufacturer settings”, and away from “disease settings”
Advanced clinical-stage pipeline
Phase IIb macrophage reprogramming for sepsis, and Phase I/II in osteoarthritis.
Short regulatory approval pathway Specialized regulation in Europe potentially enabling post-Phase II marketing approval in sepsis.
Multi-billion dollar underserved markets
Sepsis and osteoarthritis.
Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment
Cash balance supporting multiple clinical milestones within 18-24 months; Funded through end of 2025.
Date Form Description Download
Charter of the Audit Committee of the Board of Directors download
Charter of the Compensation Committee of the Board of Directors download
Code of Business Conduct and Ethics download
Disclosure Policy download
Employee Complaint Procedures for Accounting and Auditing Matters download
Insider Trading Policy download